Shenzhen-based QuantumPharm Inc., trading under the name Xtalpi Inc. (HKG: 2228), has announced a strategic partnership with the National Cancer Center Singapore (NCCS) and Duke-NUS Medical School. This collaboration will harness the power of artificial intelligence (AI) to revolutionize the discovery and design of clinical drug candidates.
AI-Driven Peptide Research for Renal Cancer
Under the terms of the agreement, Xtalpi Inc. will apply its AI-driven peptide research and design platform, which integrates automated experiments, to identify and engineer drug candidates targeting renal clear cell carcinoma (ccRCC). The targets for these drug candidates will be selected by the NCCS, a leading institution in cancer research and treatment.
Enhancing Clinical Drug Development
This partnership aims to accelerate the process of drug discovery for ccRCC, a type of kidney cancer. By combining Xtalpi Inc.’s advanced AI technology with the expertise of NCCS and Duke-NUS Medical School, the collaboration is poised to make significant strides in the development of novel therapeutics for cancer patients.
Financial Details Kept Under Wraps
While the financial aspects of this partnership have not been disclosed, the strategic importance of this alliance is clear. It represents a significant step forward in the integration of AI technology into the field of oncology, with the potential to improve treatment outcomes and save lives.Fineline Info & Tech
